💊 EDB and NMRA Partner to Boost Sri Lanka’s Pharmaceutical Exports

The Export Development Board (EDB), National Medicines Regulatory Authority (NMRA), and leading manufacturers held a crucial discussion in Colombo to address regulatory barriers and unlock the global potential of the local pharmaceutical sector. • National Target Context: The pharmaceutical manufacturing sector is positioned as a key driver to help achieve Sri Lanka's national target of US$ 36 Bn in total export earnings by 2030. Currently, export revenues remain below capacity despite significant manufacturing potential. • Regulatory Alignment: NMRA is working to align local regulatory processes with international benchmarks to boost global confidence in Sri Lankan products while maintaining national healthcare standards. • Key Challenges Identified: Manufacturers highlighted practical export bottlenecks, specifically delays in product registration, lengthy regulatory approval times, and the rapid pace of adapting to evolving compliance frameworks in target markets. • Industry Outlook: Private sector manufacturers welcomed the proactive collaboration between state bodies. Sustained public-private synergy is deemed essential for the industry to diversify export baskets and secure a stronger foothold in international markets.